Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eikon Therapeutics, Inc. (EIKN) had Return on Tangible Equity of 36.89% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-333.64M |
|
-- |
|
-- |
|
$338.94M |
|
$-338.94M |
|
$14.70M |
|
$-324.25M |
|
$-324.25M |
|
$-324.25M |
|
$-324.25M |
|
$-324.25M |
|
$-324.25M |
|
$-338.94M |
|
$-314.77M |
|
2.89M |
|
2.89M |
|
$-115.29 |
|
$-115.29 |
|
| Balance Sheet Financials | |
$348.92M |
|
$142.90M |
|
$245.82M |
|
$594.73M |
|
$55.01M |
|
-- |
|
$1.42B |
|
$1.47B |
|
$-879.03M |
|
$-879.03M |
|
$-879.03M |
|
-- |
|
| Cash Flow Statement Financials | |
$-188.52M |
|
$-181.34M |
|
$352.05M |
|
$130.88M |
|
$113.07M |
|
$-17.81M |
|
$18.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-235.26M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
36.89% |
|
|
Return on Tangible Equity |
36.89% |
-54.52% |
|
36.89% |
|
-- |
|
$-81.29 |
|
$-65.14 |
|